Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent International and its partner Genentech have completed patient enrollment in the Goal of oxidised Ldl and ACtivated macrophage Inhibition by Exposure to a Recombinant antibody (GLACIER) study of BI-204.
Subscribe to our email newsletter
Developed in collaboration with Genentech, BI-204 is a monoclonal antibody targeting oxidised forms of low-density lipoprotein cholesterol.
In the randomized placebo controlled double-blind multicenter Phase IIa study, BI-204 is delivered intravenously to 144 patients with stable atherosclerotic vascular disease.
The trial is designed to demonstrate a reduction in inflammation at the site of the inflamed atherosclerotic plaque as quantified by FDG-PET imaging at weeks four and 12.
BioInvent president and CEO Svein Mathisen said they hope to show that BI-204 is bringing the treatment of atherosclerosis and acute coronary syndromes one step forward.
The company plans to report top-line data from the study in Q3, 2012.